NuCana (NASDAQ:NCNA) Rating Lowered to Strong Sell at BidaskClub

BidaskClub downgraded shares of NuCana (NASDAQ:NCNA) from a sell rating to a strong sell rating in a research report report published on Tuesday, BidAskClub reports.

A number of other equities research analysts have also recently weighed in on the company. William Blair reaffirmed an outperform rating on shares of NuCana in a report on Thursday, May 16th. Zacks Investment Research cut Hancock Jaffe Laboratories from a buy rating to a hold rating in a report on Wednesday, June 26th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $25.50.

Shares of NASDAQ NCNA opened at $9.52 on Tuesday. The stock has a 50-day simple moving average of $11.61. NuCana has a 52-week low of $9.03 and a 52-week high of $30.10.



NuCana (NASDAQ:NCNA) last issued its earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.22). On average, equities analysts expect that NuCana will post -1.14 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Partner Fund Management L.P. raised its holdings in shares of NuCana by 14.9% during the fourth quarter. Partner Fund Management L.P. now owns 447,420 shares of the company’s stock valued at $6,488,000 after buying an additional 58,062 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of NuCana by 5.6% during the first quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock valued at $1,323,000 after buying an additional 4,160 shares during the last quarter. Marshall Wace North America L.P. raised its holdings in shares of NuCana by 558.8% during the first quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock valued at $1,034,000 after buying an additional 51,607 shares during the last quarter. Asymmetry Capital Management L.P. raised its holdings in shares of NuCana by 5.4% during the first quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock valued at $772,000 after buying an additional 2,346 shares during the last quarter. Finally, Rothschild Investment Corp IL raised its holdings in shares of NuCana by 126.1% during the second quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock valued at $291,000 after buying an additional 15,660 shares during the last quarter. 38.03% of the stock is currently owned by institutional investors.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Featured Story: How Important is Technical Analysis of Stocks

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.